---
source_pdf: "https://drive.google.com/file/d/1B9eiAuV289XKHiQYCceeiFQNGuRleQIw/view?usp=drivesdk"
drive_folder: "Portfolio/Prudentia"
type: portfolio
company: Prudentia
ingested: 2025-12-26
original_filename: "Prudentia Product.pdf"
---

> **Original:** [View Original PDF](https://drive.google.com/file/d/1B9eiAuV289XKHiQYCceeiFQNGuRleQIw/view?usp=drivesdk)

# PRUDENTIA SCIENCES

## Slide 1: Product Roadmap & Architecture

**PRUDENTIA SCIENCES**
Product Roadmap & Architecture

**Sadiqa Mahmood**
CEO and Founder
sm@prudentiasciences.com

Prepared for Virtue
Updated: July 23rd 2024

Confidential - Do not distribute

## Slide 2: Product Roadmap is Geared Towards Engagement across the Drug Life Cycle with Multiple Stakeholders

### Product Roadmap

| Category                            | Objective/Activity                | Q1 2024   | Q2 2024   | Q3 2024   | Q4 2024   | Q1 2025   | Q2 2025   | Q3 2025   | Q4 2025   |
| :---------------------------------- | :-------------------------------- | :-------- | :-------- | :-------- | :-------- | :-------- | :-------- | :-------- | :-------- |
| Clinical Program Design             | Clinical Development              | X         | X         | X         | X         | X         | X         | X         | X         |
| Optimize clinical decision making   | Enabling Platform to generate IPP | X         | X         |           |           |           |           |           |           |
|                                     | Add Quantitative Components       |           |           | X         | X         |           |           |           |           |
| M&A and Partnerships                | Business Development & Licensing  |           |           | X         | X         | X         | X         | X         | X         |
| Optimize Asset Value                | Quantitative Components           |           |           | X         | X         |           |           |           |           |
| Portfolio Strategy Planning & Management | Portfolio Strategy                |           |           |           |           | X         | X         | X         | X         |
| R&D Planning                        | Portfolio IPPS                    |           |           |           |           | X         | X         |           |           |
|                                     | Valuations & Decision Support     |           |           |           |           |           |           | X         | X         |

Confidential - Do not distribute

## Slide 3: Architectural Design

### Architectural Design

**AWS Cloud**

**APP Layer**
*   Users
*   Category/Query
*   React JS
*   node JS

**Data Layer**
*   Amazon Aurora
*   Amazon Simple Storage Service (S3)
*   Amazon Redshift

**AI/ML Layer**
*   **Data Layer**
    *   Search
    *   LLM post processing modules
    *   pgvector
    *   AWS Bedrock/LLM Deployments
    *   Search post processing modules
*   SageMaker Pipelines
*   RAG/RAFTI

Confidential - Do not distribute

## Slide 4: Prudentia's AI Approach

### Prudentia's AI Approach

*   **Neural Networks** identify temporal patterns and structures in drug development data
*   **Large Language Models** leverage existing knowledge of drugs (approved and in development) and combine advanced search technology
*   **Chain of Thought Prompting** enables generation of drug profiles with evidence justification

Confidential - Do not distribute
4

## Slide 5: Vision – End to End Portfolio Strategy and Management

### Vision – End to End Portfolio Strategy and Management

**Discovery** [Molecular structure icon]
➡️
**Commercialization** [Medicine bottle, dollar sign, stethoscope, and person icons]

**Engagement Throughout Product Life Cycle**
**Asset to Portfolio Strategy Design & Management**
**Clinical Development Plan**

**$30B- $50B TAM**

Confidential - Do not distribute
5